Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer
NCT04030429 · National Cheng-Kung University Hospital · PHASE2 · terminated · last registry update 2025-07-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Patients were recruited during screen phase but fewer patients met criteria.” | – | Registry record, National Cheng-Kung University Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MET within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-06-29Results posted on the registry: Centre Francois Baclesse, Cabozantinib (NCT04205799)
- 2026-06-23Results posted on the registry: National Cancer Institute (NCI), Savolitinib (NCT03598244)
- 2026-06-05Also stopped (suspended): Megan Kruse, MD, Taletrectinib (NCT06214793)
- 2026-06-02Phase 3 first posted: Exelixis, Cabozantinib + Zanzalintinib (NCT07620574)
- 2026-05-28Results posted on the registry: National Cancer Institute (NCI), Cabozantinib S-malate + Nivolumab (NCT04514484)
- 2026-05-08Results posted on the registry: Trisha Wise-Draper, Amivantamab (NCT05074940)
- 2026-05-05Results posted on the registry: National Cancer Institute (NCI), Cabozantinib S-malate + Nivolumab (NCT04339738)
- 2026-05-01Results posted on the registry: City of Hope Medical Center, Cabozantinib + Temozolomide (NCT04200443)
- 2026-05-01Results posted on the registry: Weill Medical College of Cornell University, Cabozantinib (NCT04631744)
- 2026-05-01Also stopped (terminated): Weill Medical College of Cornell University, Cabozantinib (NCT04631744)
- 2026-04-29Results posted on the registry: National Cancer Institute (NCI), Cabozantinib S-malate + Nivolumab (NCT03367741)
- 2026-04-23Also stopped (terminated): National Cancer Institute (NCI), Alectinib + Brigatinib (NCT03737994)
- 2026-03-27Results posted on the registry: Novartis Pharmaceuticals, Capmatinib (NCT04677595)
- 2026-03-20Results posted on the registry: National Cancer Institute (NCI), Crizotinib (NCT06360575)
- 2026-03-19Results posted on the registry: National Cancer Institute (NCI), Crizotinib (NCT06357975)
- 2026-03-19Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Cabozantinib (NCT04338269)
- 2026-03-13Results posted on the registry: University of Alabama at Birmingham, Crizotinib (NCT04283669)
- 2026-02-25Results posted on the registry: Exelixis, Cabozantinib (NCT01068782)
- 2026-02-25Also stopped (terminated): Exelixis, Cabozantinib (NCT01068782)
- 2026-02-17Also stopped (withdrawn): University of Alabama at Birmingham, Acarbose Tablets (NCT05487859)
- 2026-02-12Phase 3 first posted: Merck Sharp & Dohme LLC, Belzutifan + Nivolumab (NCT07405164)
- 2026-02-10Results posted on the registry: AstraZeneca, Osimertinib + Savolitinib (NCT03778229)
- 2026-02-09Also stopped (terminated): Genenta Science, Temferon + Pembrolizumab (NCT06716853)
- 2026-02-03Phase 3 first posted: SWOG Cancer Research Network, Axitinib + Cabozantinib (NCT07383441)
- 2026-02-02Results posted on the registry: Janssen Research & Development, LLC, Lazertinib + Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) (NCT05388669)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision